NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data

NeOnc Technologies Holdings is entering a new phase supported by fresh institutional capital, encouraging Phase 2a clinical data, and a series of open-market insider purchases. The developments are positive for the biotech's funding runway, clinical validation, and management-alignment narrative, though the article provides no funding amount, trial efficacy metrics, or share-price reaction.